|

Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

RECRUITINGSponsored by ARCAGY/ GINECO GROUP
Actively Recruiting
SponsorARCAGY/ GINECO GROUP
Started2023-12-11
Est. completion2024-12-31
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06660147

Summary

This study aims to understand whether it is possible to predict the effectiveness of maintenance treatment with PARP inhibitors following first-line chemotherapy in ovarian cancer, and thus better target the patients who benefit from this treatment

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria: Patients randomised in the PAOLA-1 study -

Exclusion Criteria:Opposition to the use of your data for research purposes.

\-

Conditions2

CancerOvarian Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.